insulin aspart vs insulin glulisine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin aspart · NovoLog
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07652528 (registry estimate)
No aligned efficacy figure on record for this race.
insulin glulisine · Apidra
Marketed by Sanofi
NCT00290927 · Phase 3 · completed
The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.
Reported efficacy
Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)
Result source: NCT00135057
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin aspart | insulin glulisine |
|---|---|---|
| HbA1c, change | -1.2% vs -1.3%vs IGlarNCT0097228319 other results
| -0.5% vs -0.5%vs Insulin LisproNCT011942582 other results
|
| Body weight, change (kg) | 2.7 vs 2.2vs Insulin GlargineNCT0488085011 other results
| 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
|
| HbA1c below 7% | 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978 | 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
|
| Fasting plasma glucose, change | -1.8 vs -1.6vs Insulin GlargineNCT048808505 other results
| —Not posted · NCT00135057 |
| 3-point MACE (% with event) | —Not posted · NCT01467323 | —Not posted · NCT00135057 |
HbA1c, change
- insulin aspart
- -1.2% vs -1.3%vs IGlarNCT00972283
19 other results
- -1.2% vs -1.2% NCT04880850
- -1.5% vs -1.4% NCT02762578
- -1.9% vs -1.7% NCT01513590
- -1.4% vs -1.4% NCT01059812
- -0.7% vs 0.1% NCT01388361
- -1.4% vs -1.2% NCT01272193
- -1.0% vs -1% NCT01045447
- -1.6% vs -1.7% NCT01045707
- -1.3% vs -1.3% NCT01009580
- -1.1% vs -1.1% NCT02648217
- -0.9% vs -1.1% NCT00972283
- -1.4% vs -1.3% NCT01045707
- -1.2% vs -1.3% NCT02453685
- -1.0% vs -1.1% NCT01165684
- -0.5% vs 0% NCT04538352
- 4.1% vs 3.4% NCT01966978
- -0.5% vs -0.5% NCT01194258
- -0.8% vs -1.1% NCT01165684
- -0.5% vs -1% NCT01165684
- insulin glulisine
- -0.5% vs -0.5%vs Insulin LisproNCT01194258
2 other results
- -2.5% vs -2.1% NCT00384085
- -0.4% vs -0.1% NCT00360698
Body weight, change (kg)
- insulin aspart
- 2.7 vs 2.2vs Insulin GlargineNCT04880850
11 other results
- 2.8 vs 2.2 NCT02762578
- 2.8 vs 2 NCT01513590
- -1 vs 0.1 NCT01388361
- 0.7 vs 0.7 NCT01272193
- 1.1 vs 1.4 NCT01059812
- 0.9 vs 0.3 NCT01474538
- -8.6 vs 1.4 NCT04538352
- -0.6 vs 3.1 NCT01966978
- 1.5 vs 1.6 NCT01194258
- 0.3 vs 0.8 NCT00998335
- 0.1 vs -0.1 NCT00842361
- insulin glulisine
- 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 1.5 vs 1.6 NCT01194258
HbA1c below 7%
- insulin aspart
- 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978
- insulin glulisine
- 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 51.1% vs 39.5% NCT00384085
Fasting plasma glucose, change
- insulin aspart
- -1.8 vs -1.6vs Insulin GlargineNCT04880850
5 other results
- -3.0 vs -1.6 NCT02762578
- -4.4 vs -3.0 NCT01513590
- -0.1 vs -1.2 NCT01388361
- -2 vs -4.4 NCT02648217
- 6.4 vs 4.9 NCT00998335
- insulin glulisine
- —Not posted · NCT00135057
3-point MACE (% with event)
- insulin aspart
- —Not posted · NCT01467323
- insulin glulisine
- —Not posted · NCT00135057
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. insulin aspart: 6 of 6 rows · insulin glulisine: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin aspart Rows use multiple source trials | insulin glulisine Rows use multiple source trials |
|---|---|---|
| Daily Plasma Glucose Change mg/dL absolute change · mmol/L | 9.44 vs 8.49 Insulin Detemir mmol/L @ 26wk*a,b NCT00998335 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 170 mg/dL as posted | -0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk*a,b NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted |
| HbA1c absolute value · percentage points | 6.7% (n=22) vs 6.9% (n=30) Insulin Detemir @ 26wka,b NCT00998335 · Phase 4 · registry result, not featured evidence · combination | 7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wka,b NCT00360698 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | 0%once weeklyc NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02453685 · Phase 4 · registry result, not featured evidence 13.9% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 5.5% NCT04880850 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 15.4%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 12.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 5.1% NCT01513590 · Phase 3 · registry result, not featured evidence 13.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 6.6%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 6.4%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 6.8%OD NCT01272193 · Phase 3 · registry result, not featured evidence 13.1%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 15.5%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 17.7% NCT01045707 · Phase 3 · registry result, not featured evidence 12.1% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence | 23.5%Lantus/Apidra-1c NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —once weeklyc NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results— NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02453685 · Phase 4 · registry result, not featured evidence 0.5% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination — NCT00591227 · Phase 4 · registry result, not featured evidence — NCT04880850 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 1.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 1% NCT01513590 · Phase 3 · registry result, not featured evidence 5.7% NCT01388361 · Phase 3 · registry result, not featured evidence · combination —IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence —IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 0.7%OD NCT01272193 · Phase 3 · registry result, not featured evidence 3.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 4.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 0%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 1.9% NCT01045707 · Phase 3 · registry result, not featured evidence 1.8% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence — NCT00842361 · Phase 2 · registry result, not featured evidence | 2.6%Lantus/Apidra-1c NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 22.5%once weeklyc NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 8.4% NCT02453685 · Phase 4 · registry result, not featured evidence 9.1% NCT01165684 · Phase 4 · registry result, not featured evidence 0% NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 7.6% NCT04880850 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 5.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 7.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence 11.8% NCT01474538 · Phase 3 · registry result, not featured evidence 6.6% NCT01513590 · Phase 3 · registry result, not featured evidence 4.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 0.7%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 4.3%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 3.4%OD NCT01272193 · Phase 3 · registry result, not featured evidence 8.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.5%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 4.3%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 11.3% NCT01045707 · Phase 3 · registry result, not featured evidence 8.5% NCT01009580 · Phase 3 · registry result, not featured evidence 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence | 11.9%Lantus/Apidra-1c NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 6.5%Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence 0%Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | once weeklyc pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 22 more resultsgi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 12.7% headache 7.2% arthralgia 6.6% NCT02453685 · Phase 4 · registry result, not featured evidence nasopharyngitis 8.1% headache 5.1% influenza 5.1% NCT01165684 · Phase 4 · registry result, not featured evidence covid-19 8.6% diarrhoea 5.2% diabetic retinopathy 4.1% NCT04880850 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.4% nasopharyngitis 8.9% headache 6.7% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.9% influenza 9% upper respiratory tract infection 7.5% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% rhinitis allergic 4.2% back pain 3.4% NCT01474538 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.7% NCT01513590 · Phase 3 · registry result, not featured evidence nausea 20.7% diarrhoea 10.3% nasopharyngitis 10.3% NCT01388361 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 9% nasopharyngitis 6% NCT01365507 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.7% nasopharyngitis 7.9% NCT01365507 · Phase 3 · registry result, not featured evidence OD nasopharyngitis 22.4% diabetic retinopathy 5.4% NCT01272193 · Phase 3 · registry result, not featured evidence BID nasopharyngitis 18.3% upper respiratory tract infection 7.5% diabetic retinopathy 6.8% NCT01059812 · Phase 3 · registry result, not featured evidence once daily nasopharyngitis 16.5% upper respiratory tract infection 16.3% headache 9.4% NCT00972283 · Phase 3 · registry result, not featured evidence once daily headache 8.7% nasopharyngitis 7.4% diarrhoea 5.2% NCT01045447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% hypertension 7.5% back pain 6% NCT01045707 · Phase 3 · registry result, not featured evidence nasopharyngitis 11.6% upper respiratory tract infection 7.6% headache 5.8% NCT01009580 · Phase 3 · registry result, not featured evidence uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence nasopharyngitis 9.1% supraventricular extrasystoles 6.1% NCT00842361 · Phase 2 · registry result, not featured evidence | c any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 3 more resultsany infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 11.9% diarrhoea 8.5% nasopharyngitis 5.1% NCT01194258 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bAssessment timepoints differ: 26 weeks versus 24 weeks.
- cPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin aspart
show 2 more results
show 2 more results
show 2 more results
show 1 more result
show 6 more results
show 1 more result
+ 40 further endpoints in the CSV export.
insulin glulisine
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · insulin glulisine's landscape